Adage Capital Partners’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,630,966
| Closed | -$190M | – | 1058 |
|
|
2025
Q4 | $190M | Buy |
2,630,966
+1,430,966
| +119% | +$92.4M | 0.29% | 63 |
|
|
2025
Q3 | $52.3M | Sell |
1,200,000
-327,000
| -21% | -$13.2M | 0.08% | 230 |
|
|
2025
Q2 | $43.4M | Sell |
1,527,000
-618,881
| -29% | -$18.4M | 0.07% | 266 |
|
|
2025
Q1 | $63.3M | Sell |
2,145,881
-606,063
| -22% | -$18.9M | 0.12% | 175 |
|
|
2024
Q4 | $80M | Sell |
2,751,944
-327,430
| -11% | -$13.7M | 0.14% | 141 |
|
|
2024
Q3 | $141M | Sell |
3,079,374
-317,608
| -9% | -$13.8M | 0.25% | 75 |
|
|
2024
Q2 | $139M | Buy |
3,396,982
+996,937
| +42% | +$28.6M | 0.26% | 73 |
|
|
2024
Q1 | $61.2M | Buy |
2,400,045
+800,045
| +50% | +$12.5M | 0.12% | 191 |
|
|
2023
Q4 | $14.5M | Buy |
1,600,000
+300,000
| +23% | +$2.01M | 0.03% | 517 |
|
|
2023
Q3 | $8.29M | Buy |
1,300,000
+550,000
| +73% | +$4.74M | 0.02% | 601 |
|
|
2023
Q2 | $8.32M | Buy |
+750,000
| New | +$9.41M | 0.02% | 599 |
|
|
2020
Q3 | – | Sell |
-25,000
| Closed | -$707K | – | 800 |
|
|
2020
Q2 | $707K | Buy |
+25,000
| New | +$721K | ﹤0.01% | 709 |
|
Other funds holding RNAM
Adage Capital Partners's RNAM Position: Q1 2026 in Review
Adage Capital Partners sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 2,630,966 shares — an estimated $190M sold.
Adage Capital Partners first reported a position in RNAM in Q2 2020 and held it in 12 quarters. The position peaked at $190M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Adage Capital Partners reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Adage Capital Partners sold 2,630,966 Avidity Biosciences shares in Q1 2026, an estimated $190M.
- Adage Capital Partners first reported a position in Avidity Biosciences in Q2 2020 and held it in 12 quarters.
- Adage Capital Partners's Avidity Biosciences position peaked at $190M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.